Vertex's Guidance Raise Is Bought, Not Grown, and the Fourth Quarter Carries the Crinetics Bill
Key Takeaways
- Revenue grew 11.8% and non-GAAP earnings per share fell 0.8%. Revenue of $3,440.8M beat consensus by 0.6%, and non-GAAP EPS of $4.76 sat at the bottom of a $4.76 to $4.92 range of published estimates. Underneath it, one month of Crinetics cost roughly $0.37 a share, and an 18.0% tax rate, 150bps below the bottom of the full-year range, added about $0.12 against a 20% rate.
- The $50M revenue guidance raise is acquired, not organic. PALSONIFY is guided at $40M to $50M, so the underlying midpoint moved $5M. The new range tops out below the $13.28B the Street carried for the year, and its midpoint implies fourth-quarter revenue flat on the third.
- The cost guide implies a fourth quarter the Street was not modelling. Combined non-GAAP operating expense rises to approximately $6.0B, which leaves about $1,745M for the fourth quarter, 13.9% above the third. On the guided lines we get fourth-quarter EPS near $3.82 against a $4.72 consensus, and full-year EPS of $17.80, 3.3% below 2025.
- The pipeline carried the quarter. AMPLIFIED's first cohort cleared the 20% to 40% proteinuria bar Vertex set for itself in May, VX-017 replaced zimislecel as the lead diabetes programme with a 2027 pivotal start, and povetacicept is 25 days from its PDUFA date. An anonymous citizen petition on IgG monitoring is the one new label risk.
- Rating: Maintaining Hold, with lower conviction. On our earnings the stock is expensive: $549.04 is 20.7% above our $455 fair value midpoint, and the stock has returned 29.4% against the S&P 500's 5.9% since initiation. We do not move to Underperform 25 days before a likely approval with three more major readouts inside twelve months. The rating now rests on the catalyst calendar, not on valuation, and we say so.
Results vs. Consensus
Q3 2026 Scorecard
| Metric | Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Total revenue | $3,440.8M | $3,419.5M | Beat | +0.6% |
| EPS (non-GAAP, diluted) | $4.76 | $4.79 | Miss | -0.6% |
| Non-GAAP operating income | $1,412.1M | $1,440M | Miss | -1.9% |
| TRIKAFTA/KAFTRIO revenue | $2,436.9M | $2,490M | Miss | -2.1% |
| EPS (GAAP, diluted) | $2.56 | n/a | n/a | -39.0% YoY |
| Non-GAAP gross margin | 85.6% | n/a | n/a | -119bps YoY |
| Combined non-GAAP R&D, AIPR&D and SG&A | $1,532.5M | n/a | n/a | +19.3% YoY |
| Non-GAAP effective tax rate | 18.0% | n/a | n/a | Below 19.5%-20.5% FY guide |
| FY26 revenue guidance (midpoint) | $13,200M | $13,280M | Below Street | -0.6% |
The EPS line needs the same caveat it needed in August. Published consensus ran from $4.76 to $4.92 across six captures, and the $4.76 actual equals the lowest of them and misses every other one. We use $4.79, the centre of the cluster, and call it a modest miss. The width of that range matters more than the miss: the providers were not agreeing on how much Crinetics cost to put into a quarter that held one month of it. The full-year row compares the new guidance midpoint with full-year revenue consensus, and the top of the new range, $13.25B, also sits below it.
Year-over-Year Comparison
| Line ($M unless noted) | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Total revenues | 3,440.8 | 3,076.4 | +11.8% |
| Cost of sales (GAAP) | 526.1 | 414.8 | +26.8% |
| Research and development (GAAP) | 1,320.6 | 977.7 | +35.1% |
| Acquired IPR&D | 40.6 | 54.5 | -25.5% |
| Selling, general and administrative (GAAP) | 844.1 | 445.1 | +89.6% |
| Total costs and expenses | 2,727.9 | 1,890.2 | +44.3% |
| Income from operations (GAAP) | 712.9 | 1,186.2 | -39.9% |
| Interest income | 118.4 | 125.7 | -5.8% |
| Interest expense | (36.0) | (3.3) | n/a |
| Other (expense) income, net | (11.9) | (9.8) | n/a |
| Provision for income taxes | 129.8 | 215.9 | -39.9% |
| Net income (GAAP) | 653.6 | 1,082.9 | -39.6% |
| Non-GAAP R&D | 935.6 | 861.1 | +8.7% |
| Non-GAAP SG&A | 556.3 | 369.0 | +50.8% |
| Combined non-GAAP R&D, AIPR&D and SG&A | 1,532.5 | 1,284.6 | +19.3% |
| Non-GAAP operating income | 1,412.1 | 1,384.8 | +2.0% |
| Non-GAAP net income | 1,213.6 | 1,236.3 | -1.8% |
| GAAP diluted EPS | $2.56 | $4.20 | -39.0% |
| Non-GAAP diluted EPS | $4.76 | $4.80 | -0.8% |
| Diluted shares (M) | 255.2 | 257.6 | -0.9% |
| GAAP gross margin | 84.71% | 86.52% | -181bps |
| Non-GAAP gross margin | 85.58% | 86.77% | -119bps |
| GAAP operating margin | 20.72% | 38.56% | -1,784bps |
| Non-GAAP operating margin | 41.04% | 45.01% | -397bps |
| Non-GAAP effective tax rate | 18.0% | 17.6% | +40bps |
The GAAP collapse is mostly mechanics. Acquisition-related costs of $502.0M sit in GAAP R&D and SG&A, and $409.6M of that is the cash cost of accelerating and settling unvested Crinetics equity awards, which the 10-Q records as post-acquisition expense rather than purchase price. Another $58.9M is transaction cost. Neither recurs. The line that will recur is the PALSONIFY intangible: $3,010.0M amortised straight-line over roughly sixteen years, about $188M a year through GAAP cost of sales. The acquired PALSONIFY inventory, $461.8M in total at fair value, carries a step-up that runs through cost of sales as Vertex sells it over about three years. The 10-Q does not split out the step-up itself. GAAP margins will run below non-GAAP margins by a wider gap than investors are used to, permanently.
Quarter-over-Quarter Comparison
| Line ($M) | Q2 2026 | Q3 2026 | QoQ |
|---|---|---|---|
| TRIKAFTA/KAFTRIO | 2,497.2 | 2,436.9 | -2.4% |
| ALYFTREK | 573.6 | 705.8 | +23.0% |
| Other CF products | 137.1 | 130.5 | -4.8% |
| Total CF | 3,207.9 | 3,273.2 | +2.0% |
| CASGEVY | 76.4 | 99.2 | +29.8% |
| JOURNAVX | 49.6 | 58.3 | +17.5% |
| PALSONIFY | 0.0 | 10.1 | n/a |
| Total revenue | 3,333.9 | 3,440.8 | +3.2% |
| Non-GAAP R&D | 888.7 | 935.6 | +5.3% |
| Acquired IPR&D | 21.4 | 40.6 | +89.7% |
| Non-GAAP SG&A | 520.2 | 556.3 | +6.9% |
| Combined non-GAAP R&D, AIPR&D and SG&A | 1,430.3 | 1,532.5 | +7.1% |
| Non-GAAP operating income | 1,423.3 | 1,412.1 | -0.8% |
| Non-GAAP net income | 1,207.3 | 1,213.6 | +0.5% |
Vertex reports three-month and nine-month columns, so the second-quarter standalone figures above come from our August note and reconcile to the nine-month columns in this release: second-quarter non-GAAP R&D of $888.7M and first-quarter $859.3M sum to the $1,748.0M the nine-month column implies before the third quarter, and the same holds for SG&A, acquired IPR&D and every product line. Non-GAAP gross margin was 85.6% in both quarters.
Quality of the beat.
- Revenue: Modest and narrower than it looks. Strip the $10.1M of PALSONIFY and organic revenue grew 11.5%, roughly 1 point of which management attributes to currency. The beat came from ALYFTREK and CASGEVY. TRIKAFTA/KAFTRIO missed its own consensus by 2.1% and declined 8.2% year over year, the steepest of its four consecutive declines, while JOURNAVX revenue grew 17.5% on more than 40% prescription growth because realised price per prescription fell.
- Margins: Gross margin held at 85.6%, in line with the full-year guide, and that is the one clean line in the print. Operating margin is a different story: non-GAAP operating margin fell 397bps year over year to 41.0%, and only about two-fifths of that is Crinetics. Standalone combined operating expense of roughly $1,472.5M still grew 14.6% year over year against 11.5% organic revenue growth.
- EPS: Low quality in both directions. Our estimate of the Crinetics drag in the quarter, from management's own components (about $60M of operating expense, about $50M of financing cost, about $15M of forgone interest income, against $10.1M of revenue), is roughly $116M pre-tax, or about $0.37 a share. Against that, the 18.0% non-GAAP tax rate sat 150bps below the bottom of the full-year range and added roughly $0.12 relative to a 20% rate. Neither number describes the run rate.
Revenue. This was a good revenue quarter that was not a better one. Growth of 11.8% compares with 12.5% in the second quarter, and the composition shifted in a direction worth watching. The United States grew 9.8% and outside the United States grew 15.6%, with Europe up 19.8%. Within cystic fibrosis the split was sharper: management put U.S. CF growth at 5% and international CF at 12%, or 10% in constant currency. The U.S. figure is the one that captures price, and the August call told us price would contribute less in the second half. It did. The consensus beat, $21.3M on $3.4B, is small enough to sit inside the PALSONIFY line and the currency effect combined.
Margins. The gross margin trajectory is now exactly on guide, and for the first time this year that is good news. The nine-month non-GAAP gross margin is 86.06%, and the reiterated "slightly below 86%" for the full year requires a fourth quarter of roughly 85.5%, close to the third quarter's 85.6%. The operating line is where the transition shows. Non-GAAP SG&A grew 50.8% year over year, with management attributing nearly 80% of the increment to commercial capability and naming povetacicept, JOURNAVX and PALSONIFY as the drivers in that order. R&D grew 8.7%, of which about $30M was Crinetics. Vertex is now paying for three commercial builds, and only one of them, JOURNAVX, has revenue large enough to see on the income statement.
EPS. Revenue grew 11.8%. Non-GAAP operating income grew 2.0%. Non-GAAP net income fell 1.8%, because net non-operating income dropped from $115.2M to $68.4M as interest expense on the new term loan arrived and interest income fell with the cash balance. Non-GAAP EPS fell 0.8%, and the 0.9% lower share count is the only reason it did not fall further. This is the first quarter in our coverage in which the decoupling we have scored as Bear 2 since initiation produced an outright year-over-year decline in earnings, and the guidance says the fourth quarter will be worse.
Segment Performance
Revenue by Product: Q3 2026
| Product ($M) | Q3 2026 | Q3 2025 | YoY | Q2 2026 | QoQ | % of total |
|---|---|---|---|---|---|---|
| TRIKAFTA/KAFTRIO | 2,436.9 | 2,653.6 | -8.2% | 2,497.2 | -2.4% | 70.8% |
| ALYFTREK | 705.8 | 247.0 | +185.7% | 573.6 | +23.0% | 20.5% |
| Other CF products | 130.5 | 139.3 | -6.3% | 137.1 | -4.8% | 3.8% |
| Total CF | 3,273.2 | 3,039.9 | +7.7% | 3,207.9 | +2.0% | 95.1% |
| CASGEVY | 99.2 | 16.9 | +487.0% | 76.4 | +29.8% | 2.9% |
| JOURNAVX | 58.3 | 19.6 | +197.4% | 49.6 | +17.5% | 1.7% |
| PALSONIFY (September only) | 10.1 | 0.0 | n/a | 0.0 | n/a | 0.3% |
| Total revenues | 3,440.8 | 3,076.4 | +11.8% | 3,333.9 | +3.2% | 100.0% |
Revenue by Geography: Q3 2026
| Region ($M) | Q3 2026 | Q3 2025 | YoY | % of total |
|---|---|---|---|---|
| United States | 2,169.1 | 1,976.3 | +9.8% | 63.0% |
| Europe | 1,002.6 | 836.9 | +19.8% | 29.1% |
| Other international | 269.1 | 263.2 | +2.2% | 7.8% |
| Total outside the United States | 1,271.7 | 1,100.1 | +15.6% | 37.0% |
| Total revenues | 3,440.8 | 3,076.4 | +11.8% | 100.0% |
Cystic Fibrosis
TRIKAFTA/KAFTRIO: the decline widened again
In August we wrote that the flagship's year-over-year decline had narrowed to 2.1%, from 7.1% in the first quarter, and treated that as the cleanest confirmation of the bull case. It reversed. TRIKAFTA/KAFTRIO fell 8.2% year over year and 2.4% sequentially to $2,436.9M, a decline of $216.7M against the prior-year quarter and the steepest of the four consecutive declines. It missed its own Street estimate by 2.1%. The prior-year comparison is not soft: the third quarter of 2025 was the strongest TRIKAFTA quarter in that year's nine-month column.
Assessment: The decline is the switch working, not demand weakening, and management's language makes that explicit. But the narrowing we called out in August was a one-quarter pattern, and anyone who extrapolated it should stop. The flagship now carries 70.8% of revenue, down from 74.9% in the second quarter, and its decline rate now sets the ceiling on what ALYFTREK has to replace.
ALYFTREK: the replacement is running, and slowing as a share of the pair
ALYFTREK grew 23.0% sequentially to $705.8M and 185.7% year over year, with nine-month revenue of $1,703.8M and U.S. year-to-date sales above $1B. Reimbursement now covers 32 countries after seven additions in the quarter. The TRIKAFTA-plus-ALYFTREK pair grew 8.3% year over year, against 13.4% in the second quarter and 7.3% in the first. ALYFTREK is now 22.5% of the pair, up from 18.7%.
"In both the US and outside The US, ALYFTREK sales continue to build primarily from patients switching from Trikafta and new patients with rare mutation." — Duncan McKechnie, Chief Commercial Officer
The first-half caveat management offered in August, that "global CF revenue growth for the first half of 2026 was 8%," and that price and currency would contribute less later in the year, turned out to be the most accurate sentence on that call. Third-quarter global CF growth was 7.7%.
Assessment: We told readers in August to carry 8% CF growth forward and not the 11% the second quarter printed. The third quarter delivered 7.7%. The pillar is intact at the rate management itself described, and the second quarter's acceleration was price and timing, not a new trajectory. The forward drivers management listed are the same four as before: rare-mutation labels, younger patients, new geographies and survival. Submissions for ALYFTREK in children aged 2 to 5 are in. None of these changes the shape of a high-single-digit annuity.
CASGEVY
CASGEVY delivered $99.2M, up 29.8% sequentially and nearly six times the prior-year quarter. More important for us, management gave the first hard infusion number since the quarterly count was withdrawn in May: approximately 200 infusions completed since launch. It also said the first nine months of 2026 infused twice as many patients as all of 2025, that more than 750 patients have been initiated since launch, and that the quarter was the fourth in a row above 100 initiations.
"We have excellent visibility into the number of infusions which is when we recognize revenue, for the rest of this year as well as into 2027. That said, infusion timing reflects patient choice with some expected seasonality in Q4 so I would encourage you to focus on the strong annual performance rather than any single quarter." — Duncan McKechnie, Chief Commercial Officer
Assessment: A cumulative count is not a quarterly count, but it is a real number, and it lets an investor check the funnel: more than 750 initiations against roughly 200 infusions means about three in four initiated patients have not yet reached infusion, whether still in collection and manufacturing or lost along the way. That is a large backlog of future revenue, and it is the best evidence yet that CASGEVY's growth is pipeline-driven rather than lumpy by accident. The fourth-quarter seasonality warning arrives with the good news and should be taken literally.
JOURNAVX
Prescriptions exceeded 750,000 in the quarter, up more than 40% sequentially and more than four times the prior-year quarter. Revenue grew 17.5% to $58.3M. The gap between those two growth rates is price, and it went the wrong way. Implied net revenue per prescription fell to about $78 from about $93 in the second quarter, roughly 16% lower, against about $108 implied across 2025.
"In addition, in Q3, gross to net and revenue were both affected by the onetime impact of securing broad Medicare Part d access in July. As that access came online, previously uncontracted prescriptions to contracted rebated pricing resulting in a 1-time reset in net revenue." — Duncan McKechnie, Chief Commercial Officer
Assessment: The demand signal is strong: JOURNAVX is now the most prescribed branded oral pain medicine in the United States, and 1.6 million patients have been treated. The revenue signal went backward for an identifiable reason, and management called the Medicare reset one-time without sizing it. The patient support programme stays on into 2027, which keeps realised price impaired for at least two more quarters. We treat revenue per prescription as the metric to watch. Our model takes the mid-2027 programme sunset at face value, so it carries no recovery toward the 50% to 60% gross-to-net level before the second half of 2027.
PALSONIFY
PALSONIFY contributed $10.1M in September, its first month inside Vertex, and approximately $24M for the full quarter including the pre-close months. Approximately 500 of the roughly 3,200 target endocrinologists are prescribing, coverage reaches about 80% of U.S. lives, and the product holds more than 40% brand share among patients starting or switching therapy. The full-year guide is $40M to $50M of Vertex-recognised revenue, which leaves about $30M to $40M for the fourth quarter.
"Approximately 500 endocrinologists are writing Palsonify, and there was a significant increase in the number of repeat writers in Q3 compared to the first half of 2026. Palsonify now has the leading brand share of over 40% among patients initiating or switching therapy." — Duncan McKechnie, Chief Commercial Officer
Assessment: The early launch metrics are good, and the economics are what they were always going to be in year one. A full-quarter run rate of about $24M sits against roughly $190M of Crinetics operating and integration expense that the guidance implies for the fourth quarter. PALSONIFY is a 2028 earnings contributor, and the European launch is not due until the second half of 2027.
Key Topics & Management Commentary
Overall Management Tone: Confident and almost entirely forward-looking, with the weight of the call on the renal pipeline and the povetacicept launch. The tone on the numbers was flatter than in August: the operating expense step-up and the financing costs were laid out once, precisely, and not defended, and nobody asked about them. The one place management was visibly careful was the povetacicept label, where every answer on IgG, manufacturing and the regulator came back to the same formula that everything expected is happening.
1. The revenue raise is Crinetics; the underlying guide did not move
Full-year revenue guidance rose to $13.15B-$13.25B from $13.10B-$13.20B, $50M at the midpoint. PALSONIFY is separately guided at $40M to $50M, and the CFO tied the raise to it directly. Stripping PALSONIFY at the midpoint, the underlying guide moved from $13,150M to $13,155M.
"The increase reflects the addition of Crinetics, which we expect to contribute $40 million to $50 million to full year 2026 revenue. The underlying drivers of our revenue outlook are unchanged." — Charles Wagner, Chief Operating Officer and Chief Financial Officer
The guide therefore did not absorb the third-quarter beat. At the midpoint, fourth-quarter revenue is $3,438.4M, flat on the third quarter and 7.8% above the $3,190.0M of the fourth quarter of 2025. Excluding roughly $35M of PALSONIFY, fourth-quarter organic revenue is about $3,403.5M, 0.8% below the third quarter and 6.7% above the prior year. Management also said there was "a high degree of certainty in our revenue guidance range" with two months left.
Assessment: A company that beats by $21M in the third quarter and then holds its underlying full-year number with two months to go is telling you the fourth quarter is softer than the run rate. The reasons are visible: CASGEVY seasonality, the JOURNAVX price reset and fading U.S. CF price. The full-year consensus of $13.28B sat above the top of the new range, so the Street's revenue line comes down even on a raise.
2. Earnings fell year over year on 12% revenue growth
Non-GAAP EPS of $4.76 compared with $4.80 a year earlier. The bridge is short. Gross profit rose $275.2M on revenue growth and a 119bps lower gross margin. Combined operating expense rose $247.9M, of which about $60M was Crinetics. Net non-operating income fell $46.8M on the term loan and the lower cash balance. The tax rate added 40bps.
"During Q3, we incurred approximately $50 million in non operating costs associated with the Crinetics transaction financing, including higher interest expense due to the new bank loans and other related costs. In addition, interest income was $15 million lower than it otherwise would have been as a result of lower cash balances after the acquisition." — Charles Wagner, Chief Operating Officer and Chief Financial Officer
On those disclosed components, the standalone business earned about $5.13 a share in the quarter, roughly 7% above the prior year, at an 18.0% tax rate that will not persist. At a 20% rate the reported $4.76 would have been about $4.64.
Assessment: The standalone business is still growing earnings in the mid-single digits on low-double-digit revenue, which is the Bear 2 pattern we have scored since initiation. What changed is that the acquisition now sits on top of it, and the combined company's earnings fell. That is not a crisis. It is a deliberate investment year getting longer, and investors are now paying 30.8 times a full-year earnings figure that will be lower than 2025's.
3. The guidance implies a fourth quarter well below the Street
Combined non-GAAP operating expense guidance moved to approximately $6.0B from $5.65B-$5.75B. Management said the standalone business remains at the high end of the old range and attributed the increase to Crinetics.
"The standalone Vertex business remains at the high end of our prior range, and the increase in guidance is attributable to the inclusion of approximately $250 million of Crinetics operating expenses and integration related costs." — Charles Wagner, Chief Operating Officer and Chief Financial Officer
Nine-month operating expense was $4,254.8M, which leaves about $1,745.2M for the fourth quarter, 13.9% above the third. Crinetics accounts for roughly $190M of that, and the standalone business for about $1,555.2M, 5.6% above its third-quarter level. Add the guided financing costs, $105M for the year of which about $55M lands in the fourth quarter, and interest income about $45M below what it would otherwise have been. On guidance-midpoint revenue, an 85.5% gross margin and a 20% tax rate, we get fourth-quarter non-GAAP EPS of about $3.82. That is 19.7% below the third quarter, 24.0% below the $5.03 of the fourth quarter of 2025, and well below the $4.72 consensus we captured the day after the print.
Assessment: This is the single most important piece of arithmetic in the release, and the call contained no question about it. Full-year EPS on our numbers is $17.80, against $18.40 in 2025 and an $18.73 consensus. Every $50M of fourth-quarter operating expense below the guide adds about $0.16, so even a generous reading leaves the year below 2025. The Street has been cutting: consensus EPS fell 9.7% over the ninety days into the print. It has more to cut.
4. Cystic fibrosis growth landed exactly where management said it would
Global CF revenue grew 7.7%. The U.S. grew 5% and international 12%, or 10% in constant currency. That is the deceleration the August call signalled, and management did not try to dress it up.
"Looking ahead, our CF growth drivers remain consistent and clear. Label expansions in rare mutations, penetration into younger age groups, additional geographies, and by the underlying survival benefit of patients on CFTR modulators." — Duncan McKechnie, Chief Commercial Officer
One sell-side question asked about the ALYFTREK trajectory, and the answer named reimbursement wins outside the U.S. and rare-mutation labels as the two drivers. Neither is a U.S. switch story.
Assessment: The CF franchise is an excellent high-single-digit business, and the third quarter showed it without price or timing tailwinds. The incremental growth is coming from outside the U.S., where pricing is lower and reimbursement wins are one-off step-ups. At 95.1% of revenue, CF growth of 7% to 8% sets the base on which every other franchise has to build, and it does not by itself support a 30x multiple.
5. CASGEVY gave a number, and a warning
The disclosure we asked for in each of the last two notes partly returned: approximately 200 infusions since launch, more than 750 initiations, and a fourth straight quarter above 100 initiations. The revenue followed, at $99.2M, up 29.8% sequentially. Combined CASGEVY and JOURNAVX revenue of $157.5M was above the roughly $151.1M a quarter the $500M target needed in the second half, and the fourth quarter now needs only $144.6M.
"In heme, CASGEVY achieved $99 million in quarterly revenue with approximately 200 infusions completed since launch and a fourth consecutive quarter with more than 100 patient initiations." — Duncan McKechnie, Chief Commercial Officer
Assessment: The $500M target is effectively met, and CASGEVY delivered 63.0% of the combined total this quarter. The seasonality warning for the fourth quarter matters for the margin rather than the target: CASGEVY carries a higher cost of goods than the CF pills, so a weaker fourth quarter for CASGEVY would help the gross margin guide while hurting revenue. We count the infusion disclosure as a genuine improvement and close the open question we have carried since May.
6. JOURNAVX: prescriptions up 40%, realised price down, support programme extended
Gross-to-net normalisation has now been described four ways in four quarters: "late 2026, early 2027" in February, "by the end of the year" in May, "the first half of 2027" in August, and now a programme sunset "by the middle of 2027," with stabilisation at a 50% to 60% gross-to-net level "at that point."
"We have chosen to leave the PSP in place and extend it into 2027 so that people who are prescribed JOURNAVX but whose plans do not yet cover it can receive the therapy. Accordingly, when we sunset the PSP mid next year, we continue to expect gross to net to stabilize at a level close to other mass market brands in the range of 50% to 60%." — Duncan McKechnie, Chief Commercial Officer
In August we wrote that a fourth slip would be a downgrade trigger. We hold that trigger as written, and by the letter it did not fire: "by the middle of 2027" is the last day of "the first half of 2027." By the spirit it came close. The date moved to the end of the window it sat in, and the quarter's realised price fell about 16% per prescription on a Medicare reset management did not size.
Assessment: Our model follows a programme sunset at mid-2027 and so carries no gross-to-net benefit until the second half of 2027. The trigger stays live: any move beyond mid-2027 fires it. The franchise itself is working, with 82% of managed lives covered and the most prescribed branded oral pain medicine in the country. But revenue of $58.3M against 750,000 prescriptions is a business priced at well under half its eventual net price, and the timing of that convergence is now the only variable in JOURNAVX revenue that matters for 2027.
7. Rare endocrine: what the purchase accounting says Vertex bought
Crinetics closed on September 1. Vertex paid $10.0B in total, $9.0B net of acquired cash and securities, and allocated $9,619.1M of it in the 10-Q. The largest single asset is not the marketed product.
| Crinetics purchase price allocation ($M) | Amount | % of allocated |
|---|---|---|
| Atumelnant in-process R&D | 5,116.0 | 53.2% |
| PALSONIFY marketed-product intangible | 3,010.0 | 31.3% |
| Goodwill | 1,335.4 | 13.9% |
| Cash, cash equivalents and marketable securities (incl. long-term) | 1,008.1 | 10.5% |
| Inventories (incl. fair-value step-up) | 461.8 | 4.8% |
| Deferred tax liability, net | (1,315.2) | -13.7% |
| Net other assets | 3.0 | 0.0% |
| Total purchase price allocated | 9,619.1 | 100.0% |
Vertex's own fair-value marks put more than half the deal in atumelnant, a Phase 3 asset in congenital adrenal hyperplasia whose adult study completes enrolment in the first quarter of 2027 and then runs 32 weeks. The Cushing's syndrome study has started, and the paediatric study is in dose ranging.
Assessment: Vertex itself values the deal more on a Phase 3 readout late in 2027 or after than on the marketed product. That is consistent with the 2029 accretion date management gave in August, a date neither the release nor the call repeated this quarter. It also changes how we score Bull 4: the pillar is less an acquired revenue stream than a second late-stage pipeline bet bundled with a small launch.
8. Povetacicept, 25 days out: a petition, a manufacturing question and a two-year commitment
The PDUFA date of November 30 is unchanged, and management described the commercial organisation as fully ready. Three new strands came up on the call. An anonymous citizen petition asks whether RAINIER's IgG monitoring and dose-hold rules should carry into the label. Two questions probed the manufacturing package. And management confirmed it will run RAINIER to full two-year kidney-function completion to support filings outside the U.S.
"Put simply, with the PDUFA date just days away now, we are 100% ready" — Duncan McKechnie, Chief Commercial Officer
On the petition, management's answer rested on the trial's monitoring cadence and its infection data: IgG measured every four weeks in more than 500 patients, no opportunistic infections, and serious infections at 0.5% in both arms. It did not give the frequency of IgG threshold excursions or dose holds, which is what the question asked.
Assessment: We still think approval on time is the likely outcome, and nothing on the call changes that. The label is now the variable. A label carrying mandatory IgG monitoring and dose-hold rules would add friction to a launch whose central claim against the incumbent is convenience: a 0.46ml monthly autoinjector at home. Management said launch metrics will come at the call at the beginning of 2027, which means the first real test of Bear 3 is the February print, not the PDUFA date.
9. AMPLIFIED cleared the bar Vertex set for it
In May Vertex pre-committed to a proteinuria improvement of 20% to 40%, or 25% to 50%, as the threshold for the expanded APOL1 population, and in August it declined to restate that bar. The data, released in September, cleared it in the first cohort: in patients with modest proteinuria, inaxaplin reduced UACR by 42.7% and UPCR by 44.7%. In the second cohort, patients with type 2 diabetes, UACR fell 17.3% and UPCR 25.4%.
"This is remarkably consistent with the treatment effect previously shared in the Phase II data in AMKD published in the New England Journal of Medicine." — Reshma Kewalramani, Chief Executive Officer and President
AMPLITUDE is now fully enrolled, with the interim analysis for potential U.S. accelerated approval in early 2027, and management named a statistically significant eGFR slope as the win condition.
Assessment: This is the single cleanest positive in the quarter, and it was delivered against a bar Vertex had set in public. The first cohort landed above the top of the 20% to 40% range and inside the 25% to 50% range management gave in the same answer. The diabetes cohort landed inside both ranges on UPCR and below both on UACR. Inaxaplin moves from a promising mechanism to a programme with consistent effect sizes across the published Phase 2 study and AMPLIFIED's first cohort. It does not yet carry value in our band, because the interim analysis that matters is a kidney-function readout, not a proteinuria readout, and it lands in early 2027.
10. Type 1 diabetes: VX-017 becomes the lead, and a timeline finally arrives
For three consecutive quarters management promised updated diabetes plans "later this year" or "in the coming months." This quarter it delivered them. VX-017, the programme designed for patients of all blood types, is now the lead, already dosing in Phase 1/2, with pivotal development planned for 2027. Zimislecel, designed for patients with blood types A or A/B only, is no longer the priority.
"The potential to bring transformative benefit to even more patients is the key reason to focus on VX-017 given the resource intensity, complexity and manufacturing demands of cell therapy programs." — Reshma Kewalramani, Chief Executive Officer and President
Assessment: The decision is sensible, and it is also a reset. The addressable population roughly doubles, to about 120,000 people, but the clock restarts from proof of concept. The phrase "resource intensity, complexity and manufacturing demands" reads as an admission that running both cell therapies to registration was not worth the resources. We continue to carry zero value for type 1 diabetes, and now with a date against which to grade the next update.
11. Next-generation CF: results Vertex calls excellent and will not advance
VX-828 data arrived as promised. In patients with the F/MF genotype on a TRIKAFTA baseline, the triple combination reduced sweat chloride by 6.6 mmol/L at four weeks and 9.4 mmol/L through four weeks. The dual combination did nothing. Vertex will not decide on any next-generation 3.0 regimen until VX-581 and VX-272 report next year.
"In short, these are excellent results. However, given the very high bar set by ALYFTREK, we intend to wait for all the data from the next gen 3.0 family before determining next steps, namely advancement into pivotal development." — Reshma Kewalramani, Chief Executive Officer and President
Assessment: This is the August gate in action: a single-digit sweat-chloride improvement on top of TRIKAFTA in eight patients is good science and not enough to beat ALYFTREK, so it waits. It confirms our reading that the CF franchise's forward value lies in labels and geography, not in a better molecule, and that the next-generation programme is mostly insurance.
12. Capital allocation and a CFO change in the middle of an integration
Cash and investments ended at $9.8B against $4.5B of term debt, roughly $5.3B net, better than the roughly $4.8B pro forma we estimated in August. The buyback slowed to about $120M for roughly 250,000 shares, from about $455M in the second quarter, with $2.5B of authorisation left. The term loan carries about 4.8% and matures in three tranches: $1.0B on August 31, 2027, $1.0B on September 1, 2028, and $2.5B on August 31, 2029. This was also the CFO's last call in that role. He becomes COO only from January 1, and the current head of finance, Jonathan Pool, becomes CFO.
"Our strategy for capital deployment remains unchanged with the priority on investing in innovation, including external innovation, and an additional allocation for share repurchases." — Charles Wagner, Chief Operating Officer and Chief Financial Officer
Assessment: The balance sheet is in better shape than we feared, and the slowed buyback is the visible cost. The phrase "including external innovation" one quarter after a $10.0B acquisition tells you business development is still the first call on capital. The CFO transition is an internal succession with continuity, since the outgoing CFO stays as COO to run the integration. The first guidance the new CFO owns is the 2027 guide in February, which will carry a full year of Crinetics costs and the first term-loan maturity.
Guidance & Outlook
| Metric (FY 2026) | Previous | Current | Change |
|---|---|---|---|
| Total revenue | $13.10B - $13.20B | $13.15B - $13.25B | Raised (+$50M midpoint, all PALSONIFY) |
| Legacy non-CF revenue (CASGEVY, JOURNAVX) | $0.5B or greater | Unchanged | Maintained |
| PALSONIFY revenue | n/a | $40M - $50M | New |
| Combined GAAP R&D, AIPR&D and SG&A | $6.30B - $6.45B | $7.15B - $7.20B | Raised (Crinetics, incl. ~$500M deal costs) |
| Combined non-GAAP R&D, AIPR&D and SG&A | $5.65B - $5.75B | Approximately $6.0B | Raised (~$250M Crinetics) |
| Non-GAAP effective tax rate | 19.5% - 20.5% | Unchanged | Maintained |
| Gross margin (call guidance) | Just under 86% | Slightly below 86% | Maintained, fourth reiteration |
| Crinetics financing costs (non-operating) | n/a | $105M | New |
| Interest income forgone after the acquisition | n/a | Approximately $60M | New |
| Foreign exchange benefit to revenue | ~150bps | ~150bps | Maintained |
The framing management chose is that the raise reflects the addition of Crinetics and that the underlying drivers are unchanged. That is accurate, and it is also the problem for anyone who modelled the third-quarter beat into the full year. The more useful reading is what the guide requires from the fourth quarter.
Implied fourth-quarter ramp: revenue of $3,388.4M to $3,488.4M, midpoint $3,438.4M, flat on the third quarter. Organic revenue excluding PALSONIFY of about $3,403.5M, down 0.8% sequentially. Combined non-GAAP operating expense of about $1,745.2M, up 13.9%. Gross margin of about 85.5%. Legacy non-CF revenue of at least $144.6M to clear $500M. Non-GAAP EPS of roughly $3.82 on our assumptions. Revenue flat, costs up 14%, earnings down 20%.
Street at: full-year revenue consensus of $13.28B was above the top of the new range, and fourth-quarter revenue consensus of $3.51B was above the $3,488.4M the top of the range permits. Full-year EPS consensus of $18.73 implies about $4.77 for the fourth quarter, against our $3.82. Some of that gap will be timing of the integration costs and some will be estimates that have not yet absorbed four months of Crinetics. Either way the direction of revision is down.
Guidance style: The pattern of three quarters holds. Vertex guides revenue conservatively and costs precisely, and every revision to a cost line this year has been toward the unfavourable end. For the third consecutive quarter there was no next-quarter revenue frame. The full-year guide with two months left now does that job, and it says the fourth quarter is the weakest earnings quarter of the year by a wide margin.
Analyst Q&A Highlights
Eleven analysts asked questions. Nine of them asked about the renal programmes, mostly povetacicept's label, manufacturing and endpoints. One asked about JOURNAVX, and two touched cystic fibrosis. None asked about the roughly $6.0B operating expense guide, the fourth-quarter earnings it implies, PALSONIFY, CASGEVY or the Crinetics economics. That is the second consecutive call on which a $10.0B acquisition drew no question at all.
Whether the IgG rules in RAINIER will follow povetacicept into the label
The first question of the call went straight to the citizen petition and asked for the data that would answer it: how often patients fell below the IgG threshold or needed treatment interruptions. The answer reframed the issue around infections rather than IgG values, and did not give the excursion frequency.
Q: "So I guess how frequently did patients actually fall below the IgG threshold or require treatment interruptions? And what do those data support or potentially indicate in terms of monitoring requirements in the commercial label?"
— Cory Kasimov, Evercore
A: "Everything that you would expect to be happening with the FDA is happening. And we are really looking forward to our PDUFA date. ... If the IgG was going to go down, we certainly would have found it because we looked and we considered a single excursion, to be worth noting. I would say the most important point to think about is infections."
— Reshma Kewalramani, Chief Executive Officer and President
Assessment: The infection data are the right clinical answer, and balanced serious infections at 0.5% in each arm are reassuring. But the question asked for a number that would tell an investor whether IgG monitoring belongs in the label, and the number did not come. The most likely reason is that the review is live and management will not pre-empt the FDA. The effect is the same either way: the label is a genuine unknown for 25 more days.
What counts as a win at the AMPLITUDE interim
Questioning asked for the bar at the inaxaplin interim on both proteinuria and kidney function. Management named one endpoint and declined to share the power assumptions.
Q: "Can you help set expectations for what would represent a win coming out of AMPLITUDE on both proteinuria and eGFR?"
— Jessica Fye, JPMorgan
A: "A win would be a statistically significant result on the GFR slope. And I say that because, of course, we are going to measure proteinuria and GFR. But our agreement with the FDA, on what would be acceptable for accelerated approval is GFR."
— Reshma Kewalramani, Chief Executive Officer and President
Assessment: Consistent with August and admirably specific. The binary is clean: a statistically significant eGFR slope difference at 48 weeks or not. A related exchange accepted an outside estimate that a 2 mL per minute benefit should be significant at twelve months. That makes the readout high-stakes in both directions, and it is the renal readout that matters most in the first half of 2027.
Whether the povetacicept manufacturing package is a review risk
A recurring line of questioning asked about manufacturing, first in general and then specifically about the use of a continuous process, which is still uncommon for biologics. The answer was a statement of comfort rather than a description of the process.
Q: "And 1 concern is around the potential use of continuous in this process. Which is relatively new for biologics at this point. So the question is, like, should we worry about it at all, or do you think the FDA has been involved enough from the beginning here for us to feel comfortable about this?"
— Multiple analysts incl. Mohit Bansal (Wells Fargo), Salveen Richter (Goldman Sachs)
A: "So we are at the point where all data has been submitted. there is an entire module on CMC and manufacturing. And, you know, we filed towards the end of March of this year. So they have had all that data now for a long time."
— Reshma Kewalramani, Chief Executive Officer and President
Assessment: Management confirmed it has used the same manufacturer from Phase 3 through filing, and the agency has had the CMC module since March. That is reassuring on process. It is not evidence about inspection outcomes, which management cannot speak to before the action date. Two of eleven analysts asking about manufacturing tells you where the Street sees residual approval risk: not efficacy, not safety, but the plant.
Why Vertex committed now to two-year kidney-function data
Questioning asked why management chose now to run RAINIER to full two-year completion, and how placebo patients who switch to another class drug would be handled. The answer tied the decision to global filings and pointed to pre-specified rules for the switching question.
Q: "Can you talk a bit more about your decision to file on 2-year eGFR data? I know you were going to make a decision. I was anticipating sometime next year. It sounds like you are making the call now."
— Akash Tewari, Jefferies
A: "So to allow preparation for everyone, we have let folks know that our intention is and our ambition is global filings, and that is gonna require 2-year GFR because ex US, not all the regulators have agreed to 1-year GFR."
— Reshma Kewalramani, Chief Executive Officer and President
Assessment: A coherent decision, with a cost. The Saudi Arabia filing for accelerated approval is already complete and under review, but filings with regulators that have not accepted one-year GFR wait for the full two-year dataset. Outside the U.S. and Saudi Arabia, povetacicept revenue is likely a 2028 event at the earliest. The switching question matters more than the answer let on: in a trial running two years into a market with approved class agents, placebo crossover to a competitor would dilute the measured kidney-function effect.
The bridge from JOURNAVX prescriptions to revenue
The only commercial question about JOURNAVX asked how prescription growth converts to revenue once the support programme ends. The answer gave the clearest statement yet of the sequencing: programme on, programme off by mid-2027, then gross-to-net at the branded norm.
Q: "But you are keeping the PSP on through the rest of the year and now pointing to gross-to-net around mid-2027. You help us think about kind of the bridge between prescription growth and eventually reported revenue as the PSP rolls off and whether you expect revenue growth to inflect as normalization occurs?"
— Evan Seigerman, BMO Capital Markets
A: "So we are taking the strategic decision to keep the PSP program switched on. We will sunset it by the middle of 2027. And at that point, you can expect, as we have said before, gross-to-net to stabilize at the sort of normal oral branded level of 50 to 60% and revenue growth to grow commensurately."
— Duncan McKechnie, Chief Commercial Officer
Assessment: "As we have said before" carries weight in that answer. The level is unchanged. The date moved in each of the three quarters before this one, and this quarter it stayed inside the August window, at its end. The answer does give the model a usable shape: a step change in realised price in the second half of 2027 on whatever prescription base exists then. With 82% of managed lives covered today, that base keeps compounding while the price waits.
How many patients are left for povetacicept
Questioning asked whether the enthusiasm for the class would translate into uptake, given that many nephrotic patients may already be on an approved agent. The answer sized the treated population as small relative to the untreated pool and deferred launch metrics to early 2027.
Q: "I am just wondering what is the right way to think about how initial uptake might balance both the growing awareness and enthusiasm versus the potential that a lot of nephrotic patients may have already come on to therapy with a drug in the class?"
— Brian Abrahams, RBC Capital Markets
A: "That leaves us with 163 thousand yet to go. ... Remember 75% of patients with IgAN have a proteinuria above 1 gram. We think there is a huge opportunity here."
— Duncan McKechnie, Chief Commercial Officer
Assessment: The market-size argument is sound. Management estimated the approved class agents would close the year with roughly 3,000 patients on therapy, so the incumbent's head start is in formulary position and prescriber habit, not in patients. The answer also confirmed that Vertex will choose its own launch metrics and present them at the start of 2027, as it did for CASGEVY. Investors should decide now which metrics they want, because the metrics a company chooses tend to be the ones that flatter its launch.
The residual unmet need in cystic fibrosis
Questioning asked how VX-828 compared with expectations and where the remaining unmet need in CF lies. The answer called the data excellent and then described a ceiling.
Q: "And then if you think about the other CFTR modulators that you have, where do you think is the biggest unmet need at this point? And where is the most room for improvement over what you have with ALYFTREK."
— Tazeen Ahmad, Bank of America
A: "So really, it is a matter of now not almost being superimposable, but being fully superimposable. So a little bit more sweat chloride, more patients getting to less than 30. that is what we are looking for."
— Reshma Kewalramani, Chief Executive Officer and President
Assessment: Management says ALYFTREK patients' sweat chloride is now nearly indistinguishable from people without CF, so the remaining gain is marginal by Vertex's own description. That protects the franchise from competitors, who must clear the same bar. It also confirms that Vertex's own CF research is defending a plateau, not building a new step.
Whether a subgroup drove the AMPLIFIED result
Questioning asked whether a small FSGS subset drove the modest-proteinuria cohort's response, and asked for the response rate across the cohort. The answer addressed the composition and not the response rate.
Q: "So just maybe, Reshma, you could provide a little bit more detail just want to ensure that there was not a small subset of FSGS patients that was driving that proteinuria reduction that was broader based. Maybe you could talk about kind of the response rate across the population in that Cohort 1."
— Terence Flynn, Morgan Stanley
A: "The majority of patients did not have FSGS. So they did not have a biopsy, and they did not have FSGS, which you would expect because their proteinuria is modest and you are correct. The response therefore was not driven by an FSGS cohort because there were not many of them."
— Reshma Kewalramani, Chief Executive Officer and President
Assessment: The composition answer removes the most obvious objection to the cohort result. The responder distribution would have shown whether the 42.7% mean came from broad effect or a few large responders, and it was not given. We weight AMPLIFIED as clearly positive with that one caveat.
What They're NOT Saying
- How often IgG fell below the RAINIER threshold. Asked directly in the first question of the call and not answered. The infection data were offered instead. With an anonymous petition asking the FDA to carry the monitoring rules into the label, the excursion frequency is the number that would let investors handicap the label, and management kept it.
- The fourth-quarter earnings arithmetic. The guide implies fourth-quarter operating expense up 13.9% sequentially on flat revenue, and roughly a 20% sequential drop in non-GAAP EPS on our numbers. Management laid out the components precisely and did not put them together, and no analyst asked.
- The 2029 accretion date for Crinetics. Given in August as the year the deal becomes accretive to non-GAAP operating income. It appears in neither the release nor the call this quarter, and the 10-Q does not use the word. A target this important is either still valid, in which case repeating it costs nothing, or it is under review.
- The size of the Medicare Part D reset in JOURNAVX revenue. Called "one-time" and not quantified. Realised price per prescription fell roughly 16% sequentially, and without the reset's size investors cannot tell how much of that is the reset and how much is a longer support programme.
- A 2027 framework of any kind. No comment on full-year Crinetics costs, which the fourth-quarter guide implies at roughly $190M a quarter, on term-loan interest at about 4.8% on $4.5B, or on the $1.0B tranche due in August 2027. The new CFO's first guide in February has to address all three.
- Tariffs. Each of the prior three releases carried a sentence saying guidance included "an immaterial cost impact from tariffs." This release does not, and neither does the 10-Q. The sentence was dropped without explanation, and no one asked about it on the call.
- The quarterly CASGEVY infusion count. The cumulative figure of approximately 200 since launch is a real improvement. The quarterly figure, published until May, has still not returned, so the third quarter's own infusion number is still not disclosed.
- The AMPLIFIED responder distribution, and the diabetes cohort against the bar. Asked for the cohort 1 response rate, management answered on FSGS composition instead. Cohort 2's UACR reduction of 17.3% fell below the bottom of the 20% to 40% bar Vertex set in May, and that went unremarked.
- A success bar for neuropathic pain beyond placebo. The diabetic peripheral neuropathy Phase 3 win was defined as beating placebo, with the gabapentin arm offered only "to give us context." In a field where placebo response runs high and gabapentin is a standard of care, the comparison against an active drug is the one physicians will read, and management set no expectation for it.
Market Reaction
- Pre-print setup: VRTX closed at $553.15 on November 2, up 22.0% year to date against the S&P 500's 10.2%, up 30.0% over the trailing twelve months, and up 9.6% over the trailing thirty days. The 52-week closing range into the print was $409.47 to $558.88, with the high set on October 30. The stock had run 15.2% from $485.22 on October 13 to $558.88 on October 30, a move that coincided with the ASN presentation and journal publication of the RAINIER interim. Since our August note it had risen 15.6% while the S&P 500 fell 2.5%.
- After-hours move: the shares rose about 1.4% after the release, and the reaction session opened at $558.44, a 1.0% gap up.
- Reaction session (November 3): the stock traded a $529.15 to $561.96 range, from -4.3% to +1.6% against the prior close, and closed at $530.76, down 4.0% or $22.39. Volume was 2.4M shares against a 1.3M thirty-day average, 1.9 times normal. The S&P 500 rose 0.4%.
- Second session (November 4): the stock closed at $549.04, up 3.4%, recovering about 82% of the prior day's loss on 1.8M shares, while the S&P 500 rose 1.6%. Across the two sessions VRTX fell 0.7% against a 2.0% gain for the index.
The intraday path on November 3 repeated August's shape at larger scale. The stock opened higher on the revenue beat and the headline raise, then sold off through the session as the cost guide was absorbed. A 5.6% swing from the high to the close on 1.9 times normal volume is what it looks like when a market works out in real time that a $50M raise is acquired revenue and that the fourth quarter carries $190M of new cost. Nothing in the coverage points to a different catalyst.
The recovery the next day is just as informative. The stock regained most of the loss in a strong tape, and the arithmetic had not changed overnight. Investors are holding VRTX for the povetacicept decision and the renal pipeline, and the earnings line is being treated as noise for now. That is a defensible position, and it puts the burden on the next two catalysts.
The wider frame is the one the rating has to answer. Since our May initiation VRTX has returned 29.4% against 5.9% for the S&P 500, about 2,350bps of relative performance against a Hold. On the same standalone basis, our FY26 EPS estimate has risen 2.4% over that period, from $18.52 to $18.96, while the multiple has gone from 22.9 times to 29.0 times. About nine-tenths of the return is multiple. On reported earnings, which now include four months of Crinetics, our estimate is $17.80 and the multiple is 30.8 times.
Street Perspective
Debate: Is Crinetics dilution a 2026 accounting event or a 2027 earnings reset?
Bull view: The bull case being made on the Street is that the dilution is front-loaded integration cost on a business bought for 2028 and beyond. PALSONIFY's launch metrics are strong, atumelnant is in Phase 3, and a $10.0B deal for two rare endocrine assets matches the specialist commercial model that built CF. On this reading the fourth quarter is a trough to look through.
Bear view: The bear camp contends that the fourth quarter is not a trough but a run rate. Roughly $190M a quarter of Crinetics cost, about $54M a quarter of term-loan interest and lower interest income persist into 2027, while PALSONIFY revenue is measured in tens of millions. Consensus EPS has fallen 9.7% in ninety days and still sits above what the guide implies.
Our take: The bears have the arithmetic and the bulls have the timeframe. Integration costs will fade, but most of the cost base is the operating expense of a Phase 3 programme and a launch, and that does not fade in 2027. We expect the February guide to show modest 2027 EPS growth off a depressed 2026 base, which flatters the growth rate and does not restore the level. The test is whether 2027 EPS clears 2025's $18.40.
Debate: Is povetacicept approval already in the price?
Bull view: A growing view on the Street is that approval on November 30 is highly likely, the commercial organisation is ready, and the untreated IgAN population is so large relative to the class's current patients that share matters less than penetration. Several desks raised targets after the print explicitly on confidence in an on-time approval.
Bear view: Skeptics argue that the late-October run already priced the approval, and that the anonymous petition makes the label the real event. Mandatory IgG monitoring or dose-hold rules would blunt a launch whose differentiation rests on home dosing and convenience. Launch metrics do not arrive until February in any case.
Our take: Approval is largely priced. The label is not. The asymmetry has narrowed from August, when the PDUFA was four months out and undated optionality still sat in the stock. A clean label probably adds a few percent, and a restrictive one probably costs more than that. That is one of the reasons we cut conviction rather than hold it.
Debate: Has CF growth peaked?
Bull view: The optimistic camp argues that 7.7% growth for a franchise of more than $13B a year in revenue is exceptional, that ALYFTREK reimbursement wins and rare-mutation labels keep adding patients, and that survival benefits lengthen the treated life of every patient already on therapy.
Bear view: The bear camp contends that U.S. CF grew only 5%, TRIKAFTA's decline widened to 8.2%, and the second quarter's acceleration was price and currency. Once the switch cohort is exhausted, the U.S. franchise is a low-single-digit business, and international growth runs on one-off reimbursement steps at lower prices.
Our take: Both sides are describing the same business. CF is a very high-quality high-single-digit annuity, which is what we have said since initiation. The bears are right that the second quarter's 11% was not a new trend. The bulls are right that nothing threatens the annuity. A franchise growing 7% to 8% inside a company whose earnings are falling does not justify 30 times earnings by itself, and the pipeline has to supply the rest.
Model Update & Valuation
| Item | Prior model (Aug 4) | Revised | Reason |
|---|---|---|---|
| FY26 total revenue | $13,150M | $13,200M | Guide midpoint; +$45M PALSONIFY, +$5M underlying |
| FY26 non-GAAP gross margin | 85.9% | 85.9% | Nine months at 86.06%; fourth quarter about 85.5% |
| FY26 combined non-GAAP opex | $5,750M | $6,000M | Standalone at the old high end, plus ~$250M Crinetics |
| FY26 net non-operating income | $425M | $316M | Less $105M financing costs and ~$60M forgone interest income, partly offset by ~$56M more interest and other income than our August model assumed |
| FY26 non-GAAP effective tax rate | 20.5% | 19.7% | Nine months at 19.6%; fourth quarter at 20% |
| FY26 diluted shares | 255.0M | 255.4M | Buyback slowed to ~$120M in the third quarter |
| FY26 non-GAAP EPS | $18.60 | $17.80 | -4.3%; -3.3% vs FY25's $18.40 |
| FY26 non-GAAP EPS, standalone (ex-Crinetics) | $18.60 | $18.96 | Tax rate of 19.7% against 20.5% (about +$0.19) and ~$56M more non-operating income (about +$0.18); standalone opex unchanged at $5,750M; drag of ~$1.17 from four months of Crinetics |
| Q4 26 non-GAAP EPS (implied) | n/a | $3.82 | Opex ~$1,745M on flat revenue; financing ~$55M |
| Povetacicept revenue | Nil in base case | Nil in base case | PDUFA November 30; launch metrics at the February call |
The build: revenue of $13,200M at 85.9% gross margin gives about $11,340M of gross profit; less $6,000M of operating expense gives $5,340M of non-GAAP operating income, a 40.5% margin; plus $316M of net non-operating income gives about $5,656M pre-tax; taxed at 19.7% gives about $4,542M of non-GAAP net income; over 255.4M diluted shares that is $17.79, which we round to $17.80. The standalone figure adds back our estimate of the Crinetics drag: $250M of operating expense, $105M of financing costs and $60M of forgone interest income, less roughly $40M of PALSONIFY gross profit, about $375M pre-tax or $1.17 a share after tax.
Valuation. At the November 4 close of $549.04 on 253.5M shares outstanding, the market capitalisation is $139.2B. Against $9.8B of cash and investments and $4.5B of term debt, net cash is about $5.3B and enterprise value about $133.9B. The stock trades at 30.8 times our reported FY26 estimate and 29.0 times our standalone estimate. On the same standalone FY26 basis, the multiple was 25.7 times in August and 22.9 times at initiation.
Fair value. We keep the 22 to 26 times band and apply it to the standalone estimate, treating Crinetics as bought at fair value. That is the assumption Vertex's own purchase accounting makes, and it avoids charging four months of integration cost against a business whose value lies in 2028 and later. On $18.96 the band is $417 to $493, midpoint $455, up from $446. The November 4 close is 20.7% above that midpoint and 11.4% above the top of the band. Applied to the reported $17.80, the band would be $392 to $463. There is no dividend.
The gap between $549.04 and our $455 midpoint is about $24B of market value. That is what investors are paying for the pipeline our band leaves out: povetacicept across three indications, inaxaplin, suzetrigine in neuropathic pain, VX-017, VX-670 and atumelnant beyond its purchase price. We do not think $24B is unreasonable for that set, and AMPLIFIED made the inaxaplin share of it more credible this quarter. We also do not think it is cheap, and several of those assets are binary inside the next twelve months.
What would move us to Outperform. Both August paths stand. The first: a povetacicept approval on or ahead of November 30, followed by a launch trajectory over the first two quarters that tracks or beats the incumbent's. The second: evidence that the JOURNAVX gross-to-net normalisation is arriving earlier than the newly-guided first half of 2027. That path did not fire, because management now ties normalisation to a programme sunset by the middle of 2027. We add a third path: a positive AMPLITUDE interim in early 2027, combined with a 2027 guide that restores EPS above 2025's $18.40.
What would move us to Underperform. The August triggers stand as written: a fourth slip in the JOURNAVX gross-to-net timeline, meaning any normalisation date beyond mid-2027; a full-year operating expense outcome above the high end of the range; or any indication that the Crinetics integration extends the earnings-growth trough beyond 2029. None fired this quarter. The gross-to-net date stayed inside the August window. The operating expense trigger is unchanged like for like: the August range excluded Crinetics, so the test is standalone spending above $5.75B, and management put standalone spending at the high end of that range, not above it. On the third, management did not repeat its 2029 accretion date, but nothing in the release, the call or the 10-Q moves the trough past 2029. We add two: a povetacicept label carrying mandatory IgG monitoring or dose holds, or a complete response letter; and a 2027 guide that implies non-GAAP EPS below 2025's $18.40.
Thesis Scorecard Post-Earnings
| Thesis Point | Status | Tag move | Notes |
|---|---|---|---|
| Bull 1: CF monopoly with a live conversion cycle | Neutral | ON TRACK (unchanged) | CF grew 7.7%, matching management's own first-half figure of 8% that we told readers to carry forward. The conversion continues, with ALYFTREK up $132.2M sequentially against a $60.3M TRIKAFTA decline, but the pair's growth slowed to 8.3% from 13.4%, and TRIKAFTA's decline widened to 8.2% from 2.1%. U.S. CF growth of 5% is the price tailwind fading as guided. |
| Bull 2: Renal as a credible fourth franchise | Confirmed | ON TRACK (unchanged) | AMPLIFIED cleared the May bar in the modest-proteinuria cohort (UACR -42.7%, UPCR -44.7%), AMPLITUDE is fully enrolled with the interim in early 2027, gMG enrolment is complete with data in the first half of 2027, and the povetacicept PDUFA date holds. The anonymous IgG petition is the new risk. Management now ranks renal as the fifth commercial pillar, after rare endocrine. |
| Bull 3: Balance sheet funds the build | Neutral | AT RISK (unchanged) | Net cash of about $5.3B is better than the roughly $4.8B pro forma we estimated. The buyback slowed to about $120M from about $455M, $2.5B of authorisation remains, and the first $1.0B term-loan tranche falls due on August 31, 2027. Management still names external innovation as a priority for capital. |
| Bull 4: Rare endocrine as a fifth pillar | Neutral | ON TRACK (unchanged) | Closed September 1. PALSONIFY's first metrics are good: about 500 prescribers, more than 40% share of starts and switches, and $10.1M in September. Vertex's own purchase accounting puts 53.2% of the allocated price in atumelnant, a Phase 3 asset, so the pillar is mostly a late-2027 readout. The fourth-quarter guide implies about $190M of Crinetics cost against about $35M of revenue. |
| Bear 1: Non-CF diversification is behind its own plan | Challenged | CONTAINED (unchanged) | CASGEVY plus JOURNAVX delivered $157.5M against the roughly $151.1M a quarter needed. The $500M target now needs $144.6M in the fourth quarter. A cumulative CASGEVY infusion count returned. The residual issue is JOURNAVX price: about $78 per prescription against about $93 in the second quarter. |
| Bear 2: Earnings growth decoupling from revenue growth | Confirmed | MATERIALIZING (unchanged) | Revenue +11.8%, non-GAAP operating income +2.0%, net income -1.8%, EPS -0.8%. The guide implies fourth-quarter EPS of about $3.82, and full-year EPS of $17.80 is 3.3% below 2025. The pattern is now visible in the reported earnings line, not just in the growth rates, and Crinetics extends it. |
| Bear 3: Povetacicept launches into an approved incumbent | Neutral | CONTAINED (unchanged) | Management sized the class at roughly 3,000 treated patients with a large untreated pool, which favours penetration over share. The new vector is the label: the anonymous petition on IgG monitoring, an answer that did not give the excursion frequency, and a convenience-led launch claim that monitoring rules would weaken. The tag moves on November 30. |
Overall: The thesis is unchanged in shape and sharper in its tension. The pipeline pillars strengthened: AMPLIFIED cleared its own bar, diabetes has a plan, and povetacicept is weeks from a decision. The earnings pillar went the other way. The combined company's earnings fell year over year for the first time in our coverage, and the guide says the fourth quarter will be the weakest of the year. Business quality is intact, earnings power for 2026 fell 4.3% on our numbers, and the stock rose anyway.
Action: Hold, with lower conviction than in August. We have been wrong on price for two consecutive quarters and we say so plainly. On valuation alone this is an Underperform: 30.8 times a falling earnings year, 20.7% above our fair value midpoint and 11.4% above the top of our band. We do not make that call 25 days before a likely approval, with an AMPLITUDE interim, neuropathic pain Phase 3 data and gMG proof of concept all due inside twelve months. The market's $24B premium for the pipeline is a fair price, and Hold is the honest rating for a fair price on a quality business. The rating is held by the calendar and not by the earnings. If the label is restrictive, or the 2027 guide leaves EPS below 2025, we move to Underperform. We would add on a pullback toward the top of our band near $493 after a clean approval. That raises the add level from the low $430s we gave in August, which was our midpoint less a normal quarter's volatility. The new level is tied to an approval: once povetacicept is on the market, the top of a band that still carries no pipeline value is a fair entry.